Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A

Toxicology and Applied Pharmacology

Volumn 289, Issue 3, 2015, Pages 442-456

  Yang, Xiaoxia ^a   Doerge, Daniel R ^a   Teeguarden, Justin G ^b,c   Fisher, Jeffrey W ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Bisphenol A; BPA; Human; PBPK; Physiologically based pharmacokinetic model

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; AIR POLLUTANT; BENZHYDRYL DERIVATIVE; PHENOL DERIVATIVE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CALCULATION; FEMALE; GLUCURONIDATION; HEART OUTPUT; HUMAN; IN VITRO STUDY; LIVER METABOLISM; MALE; MATHEMATICAL MODEL; MONTE CARLO METHOD; PHARMACOKINETICS; SENSITIVITY ANALYSIS; STOMACH EMPTYING; SYSTEMIC CIRCULATION; TISSUE PERFUSION; URINARY EXCRETION; VOLUME OF DISTRIBUTION; AIR POLLUTANT; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AIR POLLUTANTS, OCCUPATIONAL; BENZHYDRYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHENOLS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84947724439     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.10.016     Document Type: Article

References (73)

1. Audebert M., Dolo L., Perdu E., Cravedi J.P., Zalko D. Use of the gammah2ax assay for assessing the genotoxicity of bisphenol A and bisphenol F in human cell lines. Arch. Toxicol. 2011, 85:1463-1473.
2. Bartels M., Rick D., Lowe E., Loizou G., Price P., Spendiff M., et al. Development of PK- and PBPK-based modeling tools for derivation of biomonitoring guidance values. Comput. Methods Prog. Biomed. 2012, 108:773-788.
3. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
4. Biedermann S., Tschudin P., Grob K. Transfer of bisphenol A from thermal printer paper to the skin. Anal. Bioanal. Chem. 2010, 398:571-576.
5. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 1997, 13:407-484.
6. Calafat A.M., Ye X., Wong L.Y., Reidy J.A., Needham L.L. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ. Health Perspect. 2008, 116:39-44.
7. Caldwell J.H., Greenberger N.J. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication. J. Clin. Invest. 1971, 50:2626-2637.
8. CDC. 2014. Fourth national report on human exposure to environmental chemicals. Updated tables, August, 2014. Available at. Last accessed: December 15, 2014. http://www.Cdc.Gov/exposurereport/pdf/fourthreport_updatedtables_aug2014.Pdf.
9. Churchwell M.I., Camacho L., Vanlandingham M.M., Twaddle N.C., Sepehr E., Delclos K.B., et al. Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats. Toxicological Sciences: an official journal of the Society of Toxicology 2014, 139:4-20.
10. Clewell H.J., Lee T.S., Carpenter R.L. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal. 1994, 14:521-531.
11. Clewell H.J., Gentry P.R., Covington T.R., Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 2000, 108(Suppl. 2):283-305.
12. Coughlin J.L., Thomas P.E., Buckley B. Inhibition of genistein glucuronidation by bisphenol A in human and rat liver microsomes. Drug Metabolism and Disposition: the biological fate of chemicals 2012, 40:481-485.
13. Covington T.R., Robinan Gentry P., Van Landingham C.B., Andersen M.E., Kester J.E., Clewell H.J. The use of Markov chain Monte Carlo uncertainty analysis to support a public health goal for perchloroethylene. Regulatory Toxicology and Pharmacology: RTP 2007, 47:1-18.
14. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10:1093-1095.
15. Delic J.I., Lilly P.D., MacDonald A.J., Loizou G.D. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. Regulatory Toxicology and Pharmacology: RTP 2000, 32:144-155.
16. Doerge D.R., Twaddle N.C., Vanlandingham M., Brown R.P., Fisher J.W. Distribution of bisphenol A into tissues of adult, neonatal, and fetal Sprague-Dawley rats. Toxicol. Appl. Pharmacol. 2011, 255:261-270.
17. Edginton A.N., Schmitt W., Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 2006, 45:1013-1034.
18. Edginton A.N., Ritter L. Predicting plasma concentrations of bisphenol A in children younger than 2years of age after typical feeding schedules, using a physiologically based toxicokinetic model. Environ. Health Perspect. 2009, 117:645-652.
19. EFSA. 2014. Scientific opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs; question number efsa-q-2012-00423. Available at:. Last accessed: December 15, 2014. http://www.efsa.europa.eu/en/consultationsclosed/call/140117.pdf.
20. Elsby R., Maggs J.L., Ashby J., Park B.K. Comparison of the modulatory effects of human and rat liver microsomal metabolism on the estrogenicity of bisphenol A: implications for extrapolation to humans. The Journal of Pharmacology and Experimental Therapeutics 2001, 297:103-113.
21. FDA. 2014a. Bisphenol A (BPA): use in food contact application. Last assessed January 11, 2015. http://wwwfdagov/NewsEvents/PublicHealthFocus/ucm064437.htm.
22. FDA. 2014b. Memorandum: 2014 updated safety assessment of bisphenol A (BPA) for use in food contact applications. Available at. Last assessed: December 15, 2014. http://www.Fda.Gov/downloads/newsevents/publichealthfocus/ucm424266.Pdf.
23. Fisher J.W., Twaddle N.C., Vanlandingham M., Doerge D.R. Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicol. Appl. Pharmacol. 2011, 257:122-136.
24. Geens T., Aerts D., Berthot C., Bourguignon J.P., Goeyens L., Lecomte P., et al. A review of dietary and non-dietary exposure to bisphenol-A. Food and Chemical Toxicology: an international journal published for the British Industrial Biological Research Association 2012, 50:3725-3740.
25. Herman R.J., Van Pham J.D., Szakacs C.B. Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. Clin. Pharmacol. Ther. 1989, 46:18-25.
26. Hilgendorf C., Ahlin G., Seithel A., Artursson P., Ungell A.L., Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition: the biological fate of chemicals 2007, 35:1333-1340.
27. Hiller A., Nguyen N., Strassburg C.P., Li Q., Jainta H., Pechstein B., et al. Retigabine n-glucuronidation and its potential role in enterohepatic circulation. Drug Metabolism and Disposition: the biological fate of chemicals 1999, 27:605-612.
28. Ito K., Houston J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 2005, 22:103-112.
29. Jackson A.S., Stanforth P.R., Gagnon J., Rankinen T., Leon A.S., Rao D.C., et al. The effect of sex, age and race on estimating percentage body fat from body mass index: the heritage family study. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 2002, 26:789-796.
30. Kortejarvi H., Urtti A., Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur. J. Pharm. Sci. 2007, 30:155-166.
31. Kuester R.K., Sipes I.G. Prediction of metabolic clearance of bisphenol A (4,4'-dihydroxy-2,2-diphenylpropane) using cryopreserved human hepatocytes. Drug metabolism and Disposition: the biological fate of chemicals 2007, 35:1910-1915.
32. Kurebayashi H., Okudaira K., Ohno Y. Species difference of metabolic clearance of bisphenol A using cryopreserved hepatocytes from rats, monkeys and humans. Toxicol. Lett. 2010, 198:210-215.
33. Lakind J.S., Naiman D.Q. Bisphenol A (BPA) daily intakes in the United States: estimates from the 2003-2004 NHANES urinary BPA data. Journal of Exposure Science & Environmental Epidemiology 2008, 18:608-615.
34. LaKind J.S., Goodman M., Naiman D.Q. Use of NHANES data to link chemical exposures to chronic diseases: a cautionary tale. PLoS One 2012, 7.
35. Lang I.A., Galloway T.S., Scarlett A., Henley W.E., Depledge M., Wallace R.B., et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008, 300:1303-1310.
36. Matthews J.B., Twomey K., Zacharewski T.R. In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. Chem. Res. Toxicol. 2001, 14:149-157.
37. Mazur C.S., Kenneke J.F., Hess-Wilson J.K., Lipscomb J.C. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metabolism and Disposition: the biological fate of chemicals 2010, 38:2232-2238.
38. Mazur C.S., Marchitti S.A., Dimova M., Kenneke J.F., Lumen A., Fisher J. Human and rat ABC transporter efflux of bisphenol A and bisphenol A glucuronide: interspecies comparison and implications for pharmacokinetic assessment. Toxicological Sciences: an official journal of the Society of Toxicology 2012, 128:317-325.
39. Melzer D., Rice N.E., Lewis C., Henley W.E., Galloway T.S. Association of urinary bisphenol A concentration with heart disease: evidence from NHANES 2003/06. PLoS One 2010, 5.
40. Mielke H., Gundert-Remy U. Bisphenol A levels in blood depend on age and exposure. Toxicol. Lett. 2009, 190:32-40.
41. Mielke H., Partosch F., Gundert-Remy U. The contribution of dermal exposure to the internal exposure of bisphenol A in man. Toxicol. Lett. 2011, 204:190-198.
42. Mielke H., Gundert-Remy U. Physiologically based toxicokinetic modelling as a tool to support risk assessment: three case studies. Journal of Toxicology 2012, 2012:359471.
43. Miller R. Pharmacokinetics and bioavailability of ranitidine in humans. J. Pharm. Sci. 1984, 73:1376-1379.
44. Morrissey K.M., Wen C.C., Johns S.J., Zhang L., Huang S.M., Giacomini K.M. The UCSF-FDA transportal: a public drug transporter database. Clin. Pharmacol. Ther. 2012, 92:545-546.
45. Ogden C.L., Fryar C.D., Carroll M.D., Flegal K.M. Mean Body Weight, Height, and Body Mass Index, United States 1960-2002. Advance Data from Vital and Health Statistics; no 347 2004, National Center for Health Statistics, Hyattsville, Maryland.
46. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., et al. Characterization of interintestinal and intraintestinal variations in human cyp3a-dependent metabolism. The Journal of Pharmacology and Experimental Therapeutics 1997, 283:1552-1562.
47. Partosch F., Mielke H., Gundert-Remy U. Functional UDP-glucuronyltransferase 2b15 polymorphism and bisphenol A concentrations in blood: results from physiologically based kinetic modelling. Arch. Toxicol. 2013, 87:1257-1264.
48. Patterson T.A., Twaddle N.C., Roegge C.S., Callicott R.J., Fisher J.W., Doerge D.R. Concurrent determination of bisphenol A pharmacokinetics in maternal and fetal rhesus monkeys. Toxicol. Appl. Pharmacol. 2013, 267:41-48.
49. Pedersen P.V., Miller R. Pharmacokinetics of doxycycline reabsorption. J. Pharm. Sci. 1980, 69:204-207.
50. Riley R.J., McGinnity D.F., Austin R.P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition: the biological fate of chemicals 2005, 33:1304-1311.
51. Rollins D.E., Klaassen C.D. Biliary excretion of drugs in man. Clin. Pharmacokinet. 1979, 4:368-379.
52. Scheffer G.L., Kool M., de Haas M., de Vree J.M., Pijnenborg A.C., Bosman D.K., et al. Tissue distribution and induction of human multidrug resistant protein 3. Laboratory Investigation; a journal of technical methods and pathology 2002, 82:193-201.
53. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicology In Vitro: an international journal published in association with BIBRA 2008, 22:457-467.
54. Shankaran H., Adeshina F., Teeguarden J.G. Physiologically-based pharmacokinetic model for fentanyl in support of the development of provisional advisory levels. Toxicol. Appl. Pharmacol. 2013, 273:464-476.
55. Shimizu M., Ohta K., Matsumoto Y., Fukuoka M., Ohno Y., Ozawa S. Sulfation of bisphenol A abolished its estrogenicity based on proliferation and gene expression in human breast cancer mcf-7 cells. Toxicology In Vitro: an international journal published in association with BIBRA 2002, 16:549-556.
56. Silver M.K., O'Neill M.S., Sowers M.R., Park S.K. Urinary bisphenol A and type-2 diabetes in U.S. adults: data from NHANES 2003-2008. PLoS One 2011, 6:e26868.
57. Sterner T.R., Ruark C.D., Covington T.R., Yu K.O., Gearhart J.M. A physiologically based pharmacokinetic model for the oxime TMB-4: simulation of rodent and human data. Arch. Toxicol. 2013, 87:661-680.
58. Tan Y.M., Liao K.H., Conolly R.B., Blount B.C., Mason A.M., Clewell H.J. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. Journal of Toxicology and Environmental Health Part A 2006, 69:1727-1756.
59. Teeguarden J., Hanson-Drury S., Fisher J.W., Doerge D.R. Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population?. Food and Chemical Toxicology: an international journal published for the British Industrial Biological Research Association 2013, 62:949-963.
60. Teeguarden J.G., Waechter J.M., Clewell H.J., Covington T.R., Barton H.A. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicological Sciences: an official journal of the Society of Toxicology 2005, 85:823-838.
61. Teeguarden J.G., Calafat A.M., Ye X., Doerge D.R., Churchwell M.I., Gunawan R., et al. Twenty-four hour human urine and serum profiles of bisphenol A during high-dietary exposure. Toxicological Sciences: an official journal of the Society of Toxicology 2011, 123:48-57.
62. Teeguarden J.G., Twaddle N., Churchwell M.I., Yang X., Fisher J.W., Seryak L.M., et al. 24-hour human urine and serum profiles of bisphenol A: evidence against sublingual absorption following ingestion in soup. Toxicol. Appl. Pharmacol. 2015, 288(2):131-142.
63. Thayer K.A., Doerge D.R., Hunt D., Schurman S.H., Twaddle N.C., Churchwell M.I., et al. Pharmacokinetics of bisphenol A in humans following a single oral administration. Environ. Int. 2015, 83:107-115.
64. Trdan Lusin T., Roskar R., Mrhar A. Evaluation of bisphenol A glucuronidation according to UGT1A1*28 polymorphism by a new LC-MS/MS assay. Toxicology 2012, 292:33-41.
65. Twaddle N.C., Churchwell M.I., Vanlandingham M., Doerge D.R. Quantification of deuterated bisphenol A in serum, tissues, and excreta from adult Sprague-Dawley rats using liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry: RCM 2010, 24:3011-3020.
66. Vogt W. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model. Clin. Pharmacokinet. 2014, 53:51-72.
67. Volkel W., Bittner N., Dekant W. Quantitation of bisphenol A and bisphenol A glucuronide in biological samples by high performance liquid chromatography-tandem mass spectrometry. Drug Metabolism and Disposition: the biological fate of chemicals 2005, 33:1748-1757.
68. Völkel W., Colnot T., Csanady G.A., Filser J.G., Dekant W. Metabolism and kinetics of bisphenol A in humans at low doses following oral administration. Chem. Res. Toxicol. 2002, 15:1281-1287.
69. WHO. 2011. Joint FAO/WHO expert meeting to review toxicological and health aspects of bisphenol A: Final report, including report of stakeholder meeting on bisphenol A, 1-5 November 2010, Ottawa, Canada. Last assessed: August 28, 2014. http://apps.who.int/iris/bitstream/10665/44624/1/97892141564274_eng.pdf.
70. Willhite C.C., Ball G.L., McLellan C.J. Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration. Journal of Toxicology and Environmental Health Part B, Critical reviews 2008, 11:69-146.
71. Yang X., Doerge D.R., Fisher J.W. Prediction and evaluation of route dependent dosimetry of bpa in rats at different life stages using a physiologically based pharmacokinetic model. Toxicol. Appl. Pharmacol. 2013, 270:45-59.
72. Yu L.X., Lipka E., Crison J.R., Amidon G.L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 1996, 19:359-376.
73. Zalko D., Jacques C., Duplan H., Bruel S., Perdu E. Viable skin efficiently absorbs and metabolizes bisphenol A. Chemosphere 2011, 82:424-430.